Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06502964
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-09
Brief Title:
Study of ALTO-101 in Patients With Schizophrenia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Double-Blind Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 double-blind placebo-controlled two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram EEG cognitive processing markers and measures of cognition
Additional goals are to assess pharmacokinetic PK safety and tolerability of the recently developed ALTO-101T transdermal delivery system TDS formulation in a patient population
Additional goals are to assess pharmacokinetic PK safety and tolerability of the recently developed ALTO-101T transdermal delivery system TDS formulation in a patient population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None